Absci vs Antiverse (2026)
Antibodies against difficult targets are the shared ground, and the two companies split on target class, clinical stage and how they get paid. Absci designs full length antibodies from scratch with Origin-1, a generative model built for epitopes with no reported structure of an antibody or protein bound to them, then tunes the leads for potency, safety, manufacturability and half life. A wet lab of more than 77,000 square feet in Vancouver, Washington tests each round, with the ACE assay screening millions of sequence variants, and the company puts one cycle from design to tested candidate at as little as six weeks. It develops the results as its own medicines: ABS-201, aimed at the prolactin receptor, has reported interim Phase 1 data from the HEADLINE trial in androgenetic alopecia. Antiverse works only on G protein coupled receptors, ion channels and other membrane proteins. Its models write antibody and nanobody sequences from the target sequence alone, each library aimed at the part of the receptor that switches it on or blocks it, and receptor cell lines built in house test the designs in a loop that turns in about four weeks. Partners pay for the programs through upfront fees, research funding and milestones, and Nxera holds an exclusive license to what its program produces. None of the seven programs on its pipeline has entered a clinical trial. A drug company with a membrane receptor target and no antibody to start from, which wants to license the molecules and develop them itself, fits Antiverse. A partner that wants its designer to have taken an antibody of its own into people, against targets beyond membrane proteins, fits Absci.
- The epitope has no reported antibody or protein binder structure, and the design still has to land on it.
- Leads need tuning for potency, safety, manufacturability and half life alongside binding.
- Screening at the scale of millions of sequence variants per round matters to the program.
- The partner wants a designer whose own antibody has already reached a clinical trial.
- The target is a G protein coupled receptor, ion channel or other membrane protein.
- The program needs a functional agonist or antagonist, not only a binder.
- Designs have to start from the target sequence, with no ligand or binder in hand.
- The partner wants to license the resulting antibodies and run development itself.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Absci and Antiverse are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Absci | Antiverse |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2011 | Not recorded |
| Headquarters | Vancouver, Washington | Cardiff, Wales, United Kingdom |
| Website | absci.com | antiverse.io |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached.
Absci pairs Origin-1, a model that designs full length antibodies against epitopes no antibody or protein binder structure has yet been reported for, with a wet lab of more than 77,000 square feet, and takes its own designs into the clinic, where ABS-201 has interim Phase 1 data in androgenetic alopecia.
Source: AI Health Index, October 2026
Antiverse writes antibody and nanobody sequences for G protein coupled receptors and ion channels from the target sequence alone, tests them in receptor cell lines it builds in house, and licenses the results to drug company partners such as Nxera.
Source: AI Health Index, October 2026
Questions buyers ask
Which kinds of targets does each company take on?
Antiverse works only on membrane proteins such as G protein coupled receptors and ion channels, and aims each design at the part of the receptor that produces the effect a program needs. Absci samples epitope interfaces across an antigen to find the mechanism it wants, and its lead program targets the prolactin receptor. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 13, 2026. No vendor pays for placement.
How far have the antibodies from each platform advanced?
Absci's ABS-201 has reported interim Phase 1 data from the HEADLINE trial. Antiverse's PD-1 antibodies from its GlobalBio collaboration are in nonhuman primate toxicology studies, and none of its seven programs is in a clinical trial. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 13, 2026. No vendor pays for placement.
What design success figures does each one report?
Antiverse's conference posters give counts from two campaigns: 14 of 77 designed antibodies bound one receptor, and 103 of 520 binders against another were functional agonists. Absci says Origin-1 delivers specific, developable binders in fewer than one hundred designs per target. One reports outcomes from two campaigns and the other states how many designs a target takes, so the figures do not measure the same thing. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 13, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Absci is headquartered in Vancouver, Washington, with AI research labs in New York and Serbia and a drug innovation center in Zug, Switzerland. Antiverse is based in Cardiff, Wales, with offices in Boston and Prague. Neither sells software at a list price, and neither discloses the dollar terms of its partnerships.